Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/606222fc-f734-4e57-a1c5-31b70bcba69a/
VAISHALI
Vaishali Pharma LimitedSnapshot 2026-06-07 · 0.0w · Fresh
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
41.0%ile
P/E
116.2×
P/S
1.0×
P/B
1.5×
E/P
0.0086
FCF Yield
-0.174
EBITDA/EV
0.036
SH Yield
-0.224
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
59.00000000
/100 — 1=cheapest
VC2 (Trending Value)
59.00000000
/100
VC3 (Buyback)
59.00000000
/100
P/E of 116.2x is premium-priced — the market is paying up for expected growth. Negative FCF yield (-17.4%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
40.0%ile
ROE
0.013
ROA
0.007
Net Margin
0.008
Op Margin
0.060
GPA
0.111
Current
2.61
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.197
Earn Growth
-0.066
Accruals
0.172
lower=better
5yr Consist
No
Accruals ratio of 0.172 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
39.0%ile
6M Return
-13.5%
12M Return
-43.2%
12-1 Mom
-41.7%
Risk-Adj
-0.89
Vol 252d
46.9%
Vol 60d
113.2%
↑ Expanding
Max DD 12M
-60.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -42% signals a downtrend — price is moving against you. Near-term vol (113%) is expanding vs long-term (47%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.27
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare
· 160 peers
Sector Value %ile
68.9%
Sector Quality %ile
26.1%
P/E z-score
0.10
P/B z-score
-0.84
Sector Avg OS
43.8%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
| Symbol | Name | OS | Value | Quality | Momentum |
|---|---|---|---|---|---|
| NATCOPHARM | 98.0% | 88.0% | 87.0% | 81.0% | |
| UNIVPHOTO | 97.0% | 86.0% | 74.0% | 94.0% | |
| LINCOLN | 97.0% | 88.0% | 80.0% | 81.0% | |
| VENUSREM | 96.0% | 68.0% | 94.0% | 99.0% | |
| STAR | 96.0% | 73.0% | 91.0% | 91.0% | |
| HALEOSLABS | 95.0% | 82.0% | 77.0% | 81.0% | |
| AUROPHARMA | 94.0% | 71.0% | 84.0% | 87.0% | |
| SAGILITY | 93.0% | 76.0% | 81.0% | 76.0% |
Factor Interactions
Volatility Expanding
60-day vol (113%) significantly exceeds 252-day (47%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
29.5% avg (7 factors)
Quality
F
23.5% avg (7 factors)
Momentum
F
5.9% avg (4 factors)
Risk
D
38.4% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
| Factor | Current | Streak | Trend | Spark |
|---|---|---|---|---|
| OS Composite | 0.270 | —1 | — | |
| Value %ile | 0.410 | —0 | — | |
| Quality %ile | 0.400 | —0 | — | |
| Momentum %ile | 0.390 | —0 | — | |
| F-Score | 4.000 | —1 | — | |
| Confidence | 0.410 | —0 | — | |
| Volatility | 0.469 | —1 | — |
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
116.19
Earnings Yield (E/P)
0.0086
Price / Sales
0.97
Price / Book
1.46
FCF Yield
-17.4%
EBITDA / EV
3.6%
Sales Yield (1/P·S)
0.9271
Shareholder Yield
Div + net buyback / mktcap
-22.4%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
1.3%
Return on Assets
0.7%
Net Margin
0.8%
Operating Margin
6.0%
Gross Profit / Assets
Novy-Marx GPA
11.1%
Current Ratio
2.61
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.172
MomentumPrice trend strength over different horizons
6M Return
-13.5%
12M Return
-43.2%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-41.7%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.89
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
19.7%
Earnings Growth (YoY)
-6.6%
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Dividend Yield
0.0%
Buyback Yield
-22.4%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
59
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
59
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
59
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity